257 related articles for article (PubMed ID: 29843820)
1. Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature.
Nagaharu K; Masuya M; Kageyama Y; Yamaguchi T; Ito R; Kawakami K; Ito M; Katayama N
J Med Case Rep; 2018 May; 12(1):151. PubMed ID: 29843820
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
Cao H; Yamamoto K; Yang LX; Weber R
Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
[TBL] [Abstract][Full Text] [Related]
4. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment for Isolated Bone Marrow Hodgkin Lymphoma in an Human Immunodeficiency Virus (HIV)-Negative Patient.
Odeh R; Hamayel HF
Am J Case Rep; 2022 Feb; 23():e935045. PubMed ID: 35185147
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. Current developments in the treatment of early-stage classical Hodgkin lymphoma.
Borchmann S; von Tresckow B; Engert A
Curr Opin Oncol; 2016 Sep; 28(5):377-83. PubMed ID: 27455136
[TBL] [Abstract][Full Text] [Related]
8. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].
Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S
Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698
[TBL] [Abstract][Full Text] [Related]
10. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
Connors JM; Ansell SM; Fanale M; Park SI; Younes A
Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
[No Abstract] [Full Text] [Related]
11. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
12. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.
Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z
J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
14. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
15. [Durable remission attained by long-term brentuximab vedotin administration in a relapsed post-allogeneic bone marrow transplant Hodgkin lymphoma patient].
Ono Y; Hiramoto N; Yoshioka S; Yabushita T; Koba Y; Tabata S; Imai Y; Ishikawa T
Rinsho Ketsueki; 2017; 58(12):2397-2401. PubMed ID: 29332873
[TBL] [Abstract][Full Text] [Related]
16. Sequencing therapies in Hodgkin lymphoma.
Phillips EH; Collins GP; Cwynarski K
Lancet Haematol; 2021 Aug; 8(8):e537-e539. PubMed ID: 34329571
[No Abstract] [Full Text] [Related]
17. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
18. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348
[TBL] [Abstract][Full Text] [Related]
19. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA
J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]